Outpatient Treatment With Anti-Coronavirus Immunoglobulin

Eligibility Criteria

• * Clinical risk based on age ≥ 55 years or an adult (age ≥ 18 years) with an immunosuppressed condition.
• * Positive test for SARS-CoV-2 within ≤5 days (if \>1 test, the first positive is within ≤5 days). Tests may include an institutional-based nucleic acid amplification test (NAAT), or any protocol-approved rapid test.
• * Within ≤5 days from symptom onset, if symptomatic from current SARS-CoV-2 infection.
• * Agrees to not participate in another clinical trial for the treatment or management of SARS-CoV-2 infection through Day 7, or until hospitalized or significant disease progression if prior to Day 7 (defined by ordinal category 4 or 5).
• * Participant provides written informed consent prior to study procedures, and understands and agrees to adhere to planned study procedures through Day 28.
• 1. Steroids equivalent to prednisone \> 10 mg/day for at least the last 28 days
• 2. Rheumatologic or autoimmune disorder treated with a biologic or non-biologic immunosuppressive therapy
• 3. Antirejection medicine after solid organ or stem cell transplantation
• 4. Cancer treatment with systemic chemotherapy, biologic and/or cell-based therapy in the last 12 months
• 5. Primary or acquired severe B- or T-lymphocyte immune dysfunction
• 6. HIV infection
• 7. Splenectomy or functional asplenia
• * Asymptomatic and had prior symptoms from the current infection that have now resolved (for \>24 hours).
• * Asymptomatic and has received a vaccination for COVID-19 (≥1 dose).
• * Undergoing evaluation for possible admission to hospital for medical management (this does not include evaluation of possible hospitalization for public health purposes).
• * Evidence of pneumonia and/or hypoxia due to COVID-19 (NOTE: chest imaging is not required, but if available it should not show new infiltrates suggestive of pneumonia; hypoxia is defined by new oxygen supplementation or increase above pre-illness level).
• * Prior receipt of immunoglobulin product or passive immune therapy for SARS-CoV-2 in the past 90 days (i.e., convalescent plasma, SARS-CoV-2 monoclonal antibodies, or any IVIG).
• * Any of the following thrombotic or procoagulant conditions or disorders:
• 1. acute coronary syndrome, cerebrovascular syndrome, pulmonary embolism, or deep venous thrombosis within 28 days of randomization.
• 2. prothrombin gene mutation 20210, homozygous Factor V Leiden mutations, antiphospholipid syndrome, or a deficiency in antithrombin III, protein C, or protein S.
• * History of hypersensitivity to blood, plasma or IVIG excipients.
• * Known immunoglobulin A (IgA) deficiency or anti-IgA antibodies.
• * In the opinion of the investigator, any condition for which participation would not be in the best interest of the participant or that could prevent or confound protocol assessments.